-
Exelixis Announces Proposed Public Offering of 12.5M Shares
Monday, March 7, 2011 - 5:17pm | 107Exelixis, Inc. (Nasdaq: EXEL) today announced that it plans to offer, subject to market and other conditions, 12,500,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of...
-
Covance Receives AAALAC Accreditation for Its Early Development Facility in Shanghai
Monday, March 7, 2011 - 9:05am | 72Covance Inc. (NYSE: CVD) announced today that the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) awarded full accreditation to the company's early development research facility in Shanghai, China. Promoting the humane treatment of animals in science worldwide...
-
Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
Monday, March 7, 2011 - 9:01am | 123Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications. Under the agreement, WuXi will build, equip and...
-
Benzinga's Top Performing Industries, March 4th (NFLX, AXU, SCOK, MVG, HLS, DVA, A, WAT)
Friday, March 4, 2011 - 8:13pm | 251The music & video stores industry led the gainers today with an increase of 3.54%. In the space, Netflix, Inc. (NASDAQ: NFLX) gained 3.61%, and closed the session at $3.61. In the after hours, NFLX gained additional 0.84%. The nonmetallic mineral mining industry gained 2.91% as Alexco Resource...
-
SDIX Reports Fourth Quarter and Full Year 2010 Results
Thursday, March 3, 2011 - 5:10pm | 124SDIX (Nasdaq: SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, today reported financial results for the quarter and fiscal year ended December 31, 2010. Revenues for the fourth quarter...
-
Charles River to Supply Pfizer's Genetically Modified Research Models
Thursday, March 3, 2011 - 9:35am | 92Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a marketing and distribution agreement with Pfizer Inc. (NYSE: PFE) to provide certain Pfizer-developed genetically modified research models to the global biomedical research community....
-
Goldman Has Buy On Pharmaceutical Product Development (PPDI)
Thursday, March 3, 2011 - 8:40am | 176Goldman Sachs has a Buy rating and a $33 price target on shares of Pharmaceutical Product Development, Inc. (NASDAQ: PPDI). In a note to clients, Goldman writes, "PPD is our only Buy rated CRO. While we have seen a pick-up in clinical bookings across the late-stage providers, PPD...
-
Earnings Scheduled For March 3 (MRVL, HNZ, KR, NOVL, ALTH, BIG, BRLI, ACU, CLDX, ADUS, ACCL, IRWD)
Thursday, March 3, 2011 - 4:42am | 324Marvell Technology Group Ltd (NASDAQ: MRVL) is projected to report its Q4 earnings at $0.42 per share on revenue of $925.64 million. H.J. Heinz Co (NYSE: HNZ) is estimated to post its FQ3 earnings at $0.81 per share on revenue of $2.71 billion. Kroger Company (NYSE: KR) is expected to report its...
-
Kendle International Reports EPS of $0.03 vs. $0.02; Revenue $77.9M vs. $79.87M
Wednesday, March 2, 2011 - 5:46pm | 125Kendle (Nasdaq: KNDL) today reported new business awards of $152.1 million for the fourth quarter of 2010 versus $134.7 million for the fourth quarter of 2009. Gross book-to-bill improved 25 percent sequentially from the third quarter of 2010 to 2.0 in the fourth quarter. On a non-GAAP basis,...
-
UPDATE: J.P. Morgan Lowers PT on Nektar Therapeutics to $15 (NKTR)
Wednesday, March 2, 2011 - 10:37am | 110J.P. Morgan is out with its report today on Nektar Therapeutics (NASDAQ: NKTR), lowering its price target from $17 to $15. In a note to clients, J.P. Morgan writes, "Despite the disappointing performance of NKTR's shares since the surprising decision to go it along with NKTR-102 in Dec, we still...
-
Benchmark Gives Depressed Outlook For 2011 On eResearch Technology
Wednesday, March 2, 2011 - 10:05am | 169Benchmark has published a research report on a eResearch Technology (NASDAQ: ERES) after the company reported decent 4Q earnings but softness in the bookings, leading to depressed outlook for 2011. In the report, Benchmark writes "Revenue in Q4 was $44.9 million as compared with the $43.3 million...
-
Hapoalim Lowers PT on Nektar Therapeutics to $17 (NKTR)
Wednesday, March 2, 2011 - 9:28am | 122Hapoalim is out with its report on Nektar Therapeutics (NASDAQ: NKTR), lowering its price target from $19 to $17. In a note sent to clients, Hapoalim writes, "Nektar is moving slowly on the planning of its Phase 3 program for NKTR-102 in breast and ovarian cancer, implying 2012 will now be the year...
-
Deutsche Bank Lowers Its PT On Nektar Therapeutics To $14 Following Earnings Report
Wednesday, March 2, 2011 - 8:47am | 178With a steadily growing royalty stream from 9 products, 6 programs in late-stage development, and a significant early stage pipeline comprised of 9 candidates, Nektar Therapeutics (NASDAQ: NKTR) looks increasingly well positioned to participate in a number of potentially lucrative therapeutic...
-
Auriga Reiterates eResearch Buy, $10 PT (ERES)
Wednesday, March 2, 2011 - 8:44am | 83Auriga reiterated its eResearch Technology (NASDAQ: ERES) Buy rating and $10 price target in a research report published today. In the report, Auriga states, "While the Company's EPS guidance of $0.40-$0.50 was below our expectation of $0.55, we continue to believe that, at current multiples, the...
-
JP Morgan Lowers PT On Nektar Therapeutics To $15
Wednesday, March 2, 2011 - 8:40am | 27JP Morgan has lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) from $17 to $15 and maintains its Overweight rating.